Mankind Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has informed the exchanges that its Board of Directors will meet on July 31, 2025 to consider and approve the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). The Board will also consider declaration of an interim dividend, if any, for FY 2025-26. The trading window for dealing in the company's shares will remain closed until August 2, 2025, in line with SEBI's insider trading regulations. This is a routine procedural filing ahead of the quarterly results announcement.
No immediate impact on shareholders — this is a standard pre-results intimation. Investors should watch the July 31 meeting for the Q1 earnings and any announcement on interim dividend, which could be a near-term catalyst for the stock.